Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer

References

• Aagaard L, Rossi JJ. (2007). RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59:75–86.
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–10.
   PubMed Web of Science ®Google Scholar
• Buzea C, Pacheco II, Robbie K. (2007). Nanomaterials and nanoparticles: sources and toxicity. Biointerphases 2:MR17–71.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhou JL, Han X, et al. (2014). A prodrug strategy based on chitosan for efficient intracellular anticancer drug delivery. Nanotechnology 25:255101.
   PubMed Web of Science ®Google Scholar
• Chen HX, Cleck JN. (2009). Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6:465–77.
   PubMed Web of Science ®Google Scholar
• Cho SH, Noh YW, Cho MY, Lim YT. (2016). An electrostatically self-assembled ternary nanocomplex as a non-viral vector for the delivery of plasmid DNA into human adipose-derived stem cells. Molecules 21:572.
   Web of Science ®Google Scholar
• Cook KM, Figg WD. (2010). Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60:222–43.
   PubMed Web of Science ®Google Scholar
• Daka A, Peer D. (2012). RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev 64:1508–21.
   PubMed Web of Science ®Google Scholar
• Devi GR. (2006). siRNA-based approaches in cancer therapy. Cancer Gene Ther 13:819–29.
   PubMed Web of Science ®Google Scholar
• Fuchs B, Mahlum E, Halder C, et al. (2007). High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma. Gene 399:137–43.
   PubMed Web of Science ®Google Scholar
• Griffioen AW, Coenen MJ, Damen CA, et al. (1997). CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells. Blood 90:1150–9.
   PubMed Web of Science ®Google Scholar
• Han HD, Mangala LS, Lee JW, et al. (2010). Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 16:3910–22.
   PubMed Web of Science ®Google Scholar
• Katas H, Alpar HO. (2006). Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release 115:216–25.
   PubMed Web of Science ®Google Scholar
• Lallana E, Rios De La Rosa JM, Tirella A, et al. (2017). Chitosan/hyaluronic acid nanoparticles: rational design revisited for RNA delivery. Mol Pharm 14:2422–36.
   PubMed Web of Science ®Google Scholar
• Lam JK, Chow MY, Zhang Y, Leung SW. (2015). siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids 4:e252.
   PubMedGoogle Scholar
• Layzer JM, Mccaffrey AP, Tanner AK, et al. (2004). In vivo activity of nuclease-resistant siRNAs. RNA 10:766–71.
   PubMed Web of Science ®Google Scholar
• Lu C, Han HD, Mangala LS, et al. (2010). Regulation of tumor angiogenesis by EZH2. Cancer Cell 18:185–97.
   PubMed Web of Science ®Google Scholar
• Lu KV, Chang JP, Parachoniak CA, et al. (2012). VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22:21–35.
   PubMed Web of Science ®Google Scholar
• Ma S, Pradeep S, Hu W, et al. (2018). The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000Res 7:326.
   PubMedGoogle Scholar
• Mangala LS, Zuzel V, Schmandt R, et al. (2009). Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 15:3770–80.
   PubMed Web of Science ®Google Scholar
• Naito M, Azuma R, Takemoto H, et al. (2017). Multilayered polyion complexes with dissolvable silica layer covered by controlling densities of cRGD-conjugated PEG chains for cancer-targeted siRNA delivery. J Biomater Sci Polym Ed 28:1109–23.
   PubMed Web of Science ®Google Scholar
• Nasti A, Zaki NM, De Leonardis P, et al. (2009). Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimisation of the preparative process and preliminary biological evaluation. Pharm Res 26:1918–30.
   PubMed Web of Science ®Google Scholar
• Perez-Herrero E, Fernandez-Medarde A. (2015). Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52–79.
   PubMed Web of Science ®Google Scholar
• Ragelle H, Vandermeulen G, Preat V. (2013). Chitosan-based siRNA delivery systems. J Control Release 172:207–18.
   PubMed Web of Science ®Google Scholar
• Ramjiawan RR, Griffioen AW, Duda DG. (2017). Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy? Angiogenesis 20:185–204.
   PubMed Web of Science ®Google Scholar
• Rikitake Y, Hirata K, Kawashima S, et al. (2002). Involvement of endothelial nitric oxide in sphingosine-1-phosphate-induced angiogenesis. Arterioscler Thromb Vasc Biol 22:108–14.
   PubMed Web of Science ®Google Scholar
• Sennino B, Ishiguro-Oonuma T, Wei Y, et al. (2012). Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2:270–87.
   PubMed Web of Science ®Google Scholar
• Seo SH, Han HD, Noh KH, et al. (2009). Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity. Clin Exp Metastasis 26:179–87.
   PubMed Web of Science ®Google Scholar
• Swain S, Sahu PK, Beg S, Babu SM. (2016). Nanoparticles for cancer targeting: current and future directions. Curr Drug Deliv 13:1290–302.
   PubMed Web of Science ®Google Scholar
• Urban-Klein B, Werth S, Abuharbeid S, et al. (2005). RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12:461–66.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. (2012). Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499–506.
   PubMed Web of Science ®Google Scholar
• Verheul HM, Pinedo HM. (2007). Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475–85.
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. (2011). Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17:1359–70.
   PubMed Web of Science ®Google Scholar
• Xu B, Lefringhouse J, Liu Z, et al. (2017). Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy. Oncogenesis 6:e295.
   PubMed Web of Science ®Google Scholar
• Yan H, Che X, Lv Q, et al. (2017). Grifolin induces apoptosis and promotes cell cycle arrest in the A2780 human ovarian cancer cell line via inactivation of the ERK1/2 and Akt pathways. Oncol Lett 13:4806–12.
   PubMed Web of Science ®Google Scholar
• Yang MH, Jong SB, Lu CY, et al. (2012). Assessing the responses of cellular proteins induced by hyaluronic acid-modified surfaces utilizing a mass spectrometry-based profiling system: over-expression of CD36, CD44, CDK9, and PP2A. Analyst 137:4921–33.
   PubMed Web of Science ®Google Scholar
• Yang Y, Jing L, Li X, et al. (2017). Hyaluronic acid conjugated magnetic Prussian Blue@Quantum dot nanoparticles for cancer theranostics. Theranostics 7:466–81.
   PubMed Web of Science ®Google Scholar
• Zhang ZZ, Hua R, Zhang JF, et al. (2015). TEM7 (PLXDC1), a key prognostic predictor for resectable gastric cancer, promotes cancer cell migration and invasion. Am J Cancer Res 5:772–81.
   PubMed Web of Science ®Google Scholar